AZD-4041
- Generic Name
- AZD-4041
AstraZeneca Faces Safety Concerns Over Andexxa, Halts Opioid Use Disorder Drug Trial
• An FDA advisory committee reviewed AstraZeneca's application for full approval of Andexxa, raising concerns about increased thrombosis risk compared to standard care.
• Panelists debated the applicability of ANNEXA-I trial data to the broader patient population, questioning the overall benefit/risk profile of Andexxa.
• AstraZeneca discontinued a Phase II trial of AZD4041 for opioid use disorder due to potential drug-drug interactions altering the benefit-risk assessment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath